Chemically synthesized leu-enkephalin gene was fused to a large Eco RIBam HI fragment of pBR322 along with a Eco RI fragment of Ch4A phage DNA carrying the promoter and most of the E.coli e-galactosidase gene.The resulting recombinant DNA was used to transform E. coli cells. Transformants were screened for Tc-sensitivity, Am-resistance, and g-galactosidase constitutional synthesis. Restriction endonuclease analysis combined with DNA sequencing of the plasmid DNAs revealed a complete nucleotide leu-enkephalin sequence and Eco RI lac-operon fragment in two possible orientations. Radioimmunoassay for leu-enkephalin activity in BrCN-treated bacterial extracts showed that in vivo leu-enkephalin is synthesized only in strains carrying plasmids with the proper lac-fragment orientation. About 5-10 4 molecules of the former are synthesized per single E. aoli cell. One of the clones was used for leu-enkephalin purification. Using 100 g of cells it is possible to obtain about 2 mg of practically pure leu-enkephalin.
INTRODUCTION
Recent progress in methods for the chemical-enzymatic synthesis of defined polynucleotides combined with the use of recombinant DNA have provided the means for the large-scale production of various proteins by bacterial cells via cloning and expression of synthetic genes with a help of DNA vehicles. This has been aptly demonstrated in the synthesis of the somatostatin |1| and insulin |2| genes. Large-scale in vivo production of neuropeptides might be of certain practical value. The present report is concerned with the design and construction of a recombinant plasmid, carrying the synthetic leu-enkephalin gene, which codes for a neuro-pentapeptide |3|, using the aforementioned approach. Some new publications on the cloning and expression of synthetic genes have appeared |4,5| since preliminary reports |6,7| of this investigation had been published. megadaltons could be detected. In 4 of 8 analyzed clones the desired lacoperon orientation was observed (plasmids pEK-1, pEK-4, pEK-6, and pEK-9), in 3 clones it was opposite (plasmids pEK-2, pEK-10, and pEK-11). Plasmid DNAs of pEK-1 and pEK-4 were partially sequenced in order to confirm a complete leu-enkephalin gene nucleotide sequence.
MATERIALS AND METHODS

Materials
5' A-A-T-T-C-A-T-G-T-A-T-G-G-T-G-G-C-T-T-T-C-T-G-T-A-A-3' 3' G-T-A-C-A-T-A-C-C-A-C-C-G-A-A-A-G-A-C-A-T-T-C-T-
DNA-sequencing. Plasmid DNAs were digested with Eco RI, labeled with the aid of y-| 32 P| ATP and polynucleotide kinase, and then cleaved by Sail restriction endonuclease. The smaller DNA fragment supposed to contain the leu-enkephalin gene was electrophoretically purified and sequenced by Maxam and Gilbert technique [20| with several modifications |21|. Both the plasmids were found to contain a complete nucleotide sequence of the leu-enkephalin gene, attached to the altered Bam HI site of pBR322.
RESULTS AND DISCUSSION
The synthetic leu-enkephalin gene expression in E. coli cells. A number of selected clones was assayed for leu-enkephalin gene expression as described Fig. 3 . DNA sequence analysis of recombinant plasmids according to |20.211.
for somatostatin |1| with several modifications. The antibody-bound [ i)-enkephalin complex was separated from free enkephalin by retention on Millipore filters |22|. To evaluate leu-enkephalin content in bacterial extracts a competitive binding analysis was carried out using non-labeled leu-enkephalin of BrCN-treated E. ooli extracts as a competing substance. It resulted in a lowering of [ ij-enkephalin retention on the filters. The calibration controls contained various amounts of non-labeled synthetic leu-enkephalin added to a standard radioimmunoassay. Experimental data on leu-enkephalin competitive analysis is arranged in treated bacterial extracts of the four clones with proper lac-operon fragment orientation. There was no effect when extracts of the three other clones with opposite lac-fragment orientation were examined. Appropriate dilution curves (Fig. 4) According to a standard procedure cells were grown in 5 ml of LB (Luria broth) to a cell density of 10 9 cells per ml and directly used for the bacterial extract preparation or exposed to the IPTG induction. After the induction with 1 mM IPTG samples were shaken at 37°C for additional 2 h. Then cells were pelleted by centrifugation and resuspended in 1 ml of 70% HCOOH containing 5 mg of BrCN. After 24 h at 22°C in the dark extracts were diluted with 9 ml of water and evaporated. Dry residues were suspended in 0.4 ml of 50 mM Tris-HCl pH 7.0, 0.1% NaN^, and the suspension was clarified by centrifugation after pH ajustment with IM NaOH. Supernatants were saved and assayed for enkephalin content as described in Materials and Methods. Lac-operon induction by ImM isopropyl-B-thiogalactoside enhanced the extent of expression in the clones with the proper lac-operon fragment orientation 3-4 times (curve 3). Thus, it was confirmed that the constructed plasmid could direct in vivo leu-enkephalin synthesis in E. ooli cells. Leu-enkephalin purification from E. ooli pEK-6 cells. As it was estimated about 1-2-10 5 leu-enkephalin molecules are produced by a single cell in the presence of an inducer. This is 10 times higher than observed with somatostatin expression |1| and similar to A and B insulin chain synthesis |2|. Thus, 100 g of packed cells contain at least 5 mg of fused leu-enkephalin. We therefore undertook purification on the former. HC1 at 105 C under vacuum for 24 h and analyzed for amino acid composition |23| using analyzer model D-500, Durrum. The results are shown in Table 3 . It can be seen that amino acid composition of the purified pentapeptide is completely identical to the standard leu-enkephalin. Slight reduction in tyrosine content was due to a partial degradation of tyrosine molecules under conditions specified.
This work was carried out in accordance with current USSR guidelines on 
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Samples of the standard leu-enkephalin and of that purified from pEK-6 E. coli cells were hydrolyzed in 5.7 M HC1 at 105°C under vacuum for 24 h. Amino acid analysis was carried out as described |23|. Amino acid contamination in both samples was less than 10% compared to the figures given in the table.
recombinant DNA research with P3 physical containment facilities employed.
